-
公开(公告)号：EP3904366A1
公开(公告)日：2021-11-03
申请号：EP20197788.1
申请日：2015-12-16
申请人： Novartis AG
发明人： BARNES-SEEMAN, David , COHEN, Scott Louis , DIENER, John Louis , GAMPE, Christian , ROACHE, James , WHITE, Amy , WILLIAMS, Sarah , YUAN, Jun , ZECRI, Frederic
IPC分类号： C07H19/167 , C07H21/02 , C07F9/38 , C07F9/6561 , C07H19/207
摘要： The disclosure relates to nucleic acids that contain modifications at the 5'-end, 3'-end or 5'-end and 3'-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.The compounds are of formula (I)
-
2.发明公开
公开(公告)号：EP4259661A1
公开(公告)日：2023-10-18
申请号：EP21830780.9
申请日：2021-12-13
申请人： Novartis AG
发明人： ADACHI, Yuichiro , ALLPORT-ANDERSON, Jennifer R. , COUGHLIN, Shaun R. , DIENER, John Louis , GADTKE, Lars , HARTLEPP, Felix , HU, Tiancen , KOCH, Alexander Wolfgang , LADETZKI-BAEHS, Kathrin , ROMANOWSKI, Michael John , RUSSO, Cesare , WEZLER, Xenia Karola , XIE, Xiaoling
IPC分类号： C07K16/28 , A61P9/12 , A61K39/395 , A61K39/00
-
公开(公告)号：EP3983437A1
公开(公告)日：2022-04-20
申请号：EP20733037.4
申请日：2020-06-10
申请人： Novartis AG
-
-
公开(公告)号：EP3233880A1
公开(公告)日：2017-10-25
申请号：EP15823199.3
申请日：2015-12-16
申请人： Novartis AG
发明人： BARNES-SEEMAN, David , COHEN, Scott Louis , DIENER, John Louis , GAMPE, Christian , ROACHE, James , WHITE, Amy , WILLIAMS, Sarah , YUAN, Jun , ZECRI, Frederic
IPC分类号： C07H19/167 , C07H21/02 , C07F9/38
CPC分类号： C07H21/02 , C07F9/65616 , C07H19/167 , C07H19/207 , C07K14/5759
摘要： The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids arc disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
摘要翻译： 本公开涉及在5'-末端，3'-末端或5'-末端和3'-末端含有修饰的核酸，并且公开了可用于制备修饰的核酸的化合物。 与未修饰的核酸相比，修饰的核酸具有改善的表达，较低的免疫原性和改善的稳定性。
-
6.发明公开METHODS OF TREATING METABOLIC DISORDERS ASSOCIATED WITH LIPODYSTROPHIES AND DEFECTS IN INSULIN PRODUCTION OR SIGNALING 审中-公开方法代谢紊乱的治疗确诊脂肪营养障碍和缺陷的联系胰岛素产生或信号
公开(公告)号：EP3125921A1
公开(公告)日：2017-02-08
申请号：EP15710087.6
申请日：2015-03-09
申请人： Novartis AG
摘要： The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.
摘要翻译： 本发明涉及的用于FGF21多肽或蛋白，或突变体，变体的新的治疗方法，和融合的识别物，例如，在胰岛素信号治疗代谢性疾病相关联的缺陷（例如胰岛素受体突变病症（INSR障碍）和/ 或自身免疫性胰岛素受体紊乱（B型胰岛素抵抗）），检查作为1型糖尿病，混合型血脂异常，非酒精性脂肪肝疾病（NAFLD），和其他代谢障碍，以及各种脂肪营养障碍中胰岛素产生的缺陷：如HIV-HAART诱导的局部 -lipodystrophy，并降低重症病人的死亡率和发病率。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.017 秒)
